MediciNova (MNOV) Receives Daily Coverage Optimism Rating of 0.02
Headlines about MediciNova (NASDAQ:MNOV) have trended somewhat positive on Thursday, AlphaOne Sentiment Analysis reports. The research group, a subsidiary of Accern, identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MediciNova earned a media sentiment score of 0.02 on AlphaOne’s scale. AlphaOne also assigned news stories about the biopharmaceutical company an impact score of 59 out of 100, indicating that recent media coverage is somewhat likely to have an effect on the stock’s share price in the near term.
Separately, Credit Suisse Group AG assumed coverage on shares of MediciNova in a report on Tuesday. They issued an “outperform” rating on the stock.
MediciNova (NASDAQ:MNOV) traded up 0.35% during midday trading on Thursday, hitting $5.75. 66,047 shares of the stock traded hands. MediciNova has a 12-month low of $4.85 and a 12-month high of $8.69. The firm’s 50 day moving average is $5.81 and its 200-day moving average is $6.44. The stock’s market capitalization is $198.53 million.
Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).
Receive News & Ratings for MediciNova Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.